144 related articles for article (PubMed ID: 9988231)
1. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K; Maguire T; McGreal G; McDermott E; O'Higgins N; Duffy MJ
Int J Cancer; 1999 Feb; 84(1):44-8. PubMed ID: 9988231
[TBL] [Abstract][Full Text] [Related]
2. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
Remacle AG; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
Br J Cancer; 1998 Mar; 77(6):926-31. PubMed ID: 9528836
[TBL] [Abstract][Full Text] [Related]
3. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix.
Davidson B; Goldberg I; Liokumovich P; Kopolovic J; Gotlieb WH; Lerner-Geva L; Reder I; Ben-Baruch G; Reich R
Int J Gynecol Pathol; 1998 Oct; 17(4):295-301. PubMed ID: 9785129
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
[TBL] [Abstract][Full Text] [Related]
5. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer.
Gress TM; Müller-Pillasch F; Lerch MM; Friess H; Büchler M; Adler G
Int J Cancer; 1995 Aug; 62(4):407-13. PubMed ID: 7635566
[TBL] [Abstract][Full Text] [Related]
6. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma.
Laird SM; Dalton CF; Okon MA; Bunning RA; Marshall R; Li TC
J Reprod Fertil; 1999 Mar; 115(2):225-32. PubMed ID: 10434927
[TBL] [Abstract][Full Text] [Related]
7. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues.
Kawashima Y; Saika S; Yamanaka O; Okada Y; Ohkawa K; Ohnishi Y
Curr Eye Res; 1998 Apr; 17(4):445-51. PubMed ID: 9561837
[TBL] [Abstract][Full Text] [Related]
8. A study of metalloproteinases in fifty joint fluid specimens.
Gaudin P; Razakaboay M; Surla A; Berthier S; Fauconnier J; Morel F; Phelip X
Rev Rhum Engl Ed; 1997 Jun; 64(6):375-81. PubMed ID: 9513609
[TBL] [Abstract][Full Text] [Related]
9. Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis.
Gomez DE; De Lorenzo MS; Alonso DF; Andrade ZA
Am J Trop Med Hyg; 1999 Jul; 61(1):9-13. PubMed ID: 10432047
[TBL] [Abstract][Full Text] [Related]
10. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
Thomas CV; Coker ML; Zellner JL; Handy JR; Crumbley AJ; Spinale FG
Circulation; 1998 May; 97(17):1708-15. PubMed ID: 9591765
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors.
Murashige M; Miyahara M; Shiraishi N; Saito T; Kohno K; Kobayashi M
Jpn J Clin Oncol; 1996 Oct; 26(5):303-9. PubMed ID: 8895669
[TBL] [Abstract][Full Text] [Related]
13. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
14. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
Iwata H; Kobayashi S; Iwase H; Masaoka A; Fujimoto N; Okada Y
Jpn J Cancer Res; 1996 Jun; 87(6):602-11. PubMed ID: 8766524
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
[TBL] [Abstract][Full Text] [Related]
16. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
17. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta.
Huppertz B; Kertschanska S; Demir AY; Frank HG; Kaufmann P
Cell Tissue Res; 1998 Jan; 291(1):133-48. PubMed ID: 9394051
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
20. 72-kDa and 92-kDa gelatinases in saliva of patients with human immunodeficiency virus infection.
Mellanen L; Salo T; Ingman T; Konttinen YT; Lähdevirta J; Sorsa T
Acta Odontol Scand; 1998 Jun; 56(3):135-42. PubMed ID: 9688221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
